Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

CANTARGIA Aktie

>CANTARGIA Performance
1 Woche: -1,0%
1 Monat: -14,6%
3 Monate: -2,8%
6 Monate: +59,6%
1 Jahr: +259,9%
laufendes Jahr: -2,8%
>CANTARGIA Aktie
Name:  CANTARGIA AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0006371126 / A2JAZX
Symbol/ Ticker:  7V3 (Frankfurt)
Kürzel:  FRA:7V3, ETR:7V3, 7V3:GR
Index:  -
Webseite:  https://cantargia.com/
Profil:  Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface recepto..
>Volltext..
Marktkapitalisierung:  95.48 Mio. EUR
Unternehmenswert:  69.53 Mio. EUR
Umsatz:  29.69 Mio. EUR
EBITDA:  14.78 Mio. EUR
Nettogewinn:  13.78 Mio. EUR
Gewinn je Aktie:  0.06 EUR
Schulden:  -
Liquide Mittel:  26.42 Mio. EUR
Operativer Cashflow:  14.07 Mio. EUR
Bargeldquote:  9.41
Umsatzwachstum:  -
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CANTARGIA
Letzte Datenerhebung:  05.04.26
>CANTARGIA Kennzahlen
Aktien/ Unternehmen:
Aktien: 248.61 Mio. St.
Frei handelbar: 95.26%
Leerverk. Aktien: -
Rückkaufquote: -10.49%
Mitarbeiter: 22
Umsatz/Mitarb.: 1.35 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 111.28%
Bewertung:
KGV: 7.45
KGV lG: -
KUV: 3.21
KBV: 4.12
PEG-Ratio: -
EV/EBITDA: 4.7
Rentabilität:
Bruttomarge: -
Gewinnmarge: 46.41%
Operative Marge: 48.75%
Managementeffizenz:
Gesamtkaprendite: 62.93%
Eigenkaprendite: 76.91%
>CANTARGIA Peer Group
Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung
 
05.03.26 - 10:31
Cantargia to Participate at Van Lanschot Kempen′s Life Sciences Conference (Accesswire)
 
LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings......
23.02.26 - 09:30
Cantargia to Participate in TD Cowen′s Annual Healthcare Conference (Accesswire)
 
LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meet......
20.02.26 - 07:30
Cantargia Publishes Full Year Report 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.can......
06.02.26 - 11:30
Invitation to the Presentation of Cantargia′s Annual Results for 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CE......
28.01.26 - 10:30
Cantargia to Participate at Leerink Partners Global Healthcare Conference (Accesswire)
 
LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-o......
23.01.26 - 08:06
Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study (Accesswire)
 
LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in comb......
05.12.25 - 08:06
Cantargia Provides Update on Overall Survival Data from TRIFOUR (Accesswire)
 
LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study......
19.11.25 - 16:06
Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse/n (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
19.11.25 - 07:30
Cantargia Publishes Interim Report for January to September 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on ......
12.11.25 - 09:07
Cantargia Presents Nomination Committee Ahead of 2026 AGM (Accesswire)
 
LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appoint......
05.11.25 - 09:54
Invitation to the Presentation of Cantargia′s Interim Report January-September 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on W......
23.10.25 - 13:54
Cantargia to Participate in Upcoming Conferences (Accesswire)
 
LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel......
02.10.25 - 08:06
Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer (Accesswire)
 
LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical......
01.10.25 - 00:30
Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC (Accesswire)
 
LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while thi......
11.09.25 - 08:06
Cantargia Closes the Acquisition of CAN10 by Otsuka (Accesswire)
 
LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Ot......
27.08.25 - 08:06
Cantargia Granted Important US Patent for Nadunolimab (Accesswire)
 
LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the pa......
21.08.25 - 07:30
Cantargia Publishes Half-Year Report 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO ......
18.08.25 - 18:54
Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer (Accesswire)
 
Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and bu......
12.08.25 - 10:42
Invitation to the Presentation of Cantargia′s H1 2025 Report (Accesswire)
 
LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August......
17.07.25 - 21:54
Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (Accesswire)
 
LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolera......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das sind halt die Freuden eines Preisministers, wenn ab und zu nicht alles teurer wird. - Dr. Josef Staribacher
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!